Breaking News, Collaborations & Alliances

IAVI, BARDA Expand Partnership to Advance Filovirus Vaccine Candidates

The funding from BARDA will enable IAVI to continue critical development and testing of filovirus vaccine candidates to facilitate better preparedness.

International AIDS Vaccine Initiative (IAVI) announced the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, funded additional development and testing of IAVI’s single-dose vaccine candidates against the filoviruses Marburg virus (MARV) and Sudan ebolavirus (SUDV). BARDA’s US$30 million award to IAVI expands the agency’s existing support o...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters